Oestrogen receptor status, treatment and breast cancer prognosis in Icelandic BRCA2 mutation carriers.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
AuthorsJonasson, Jon G
Stefansson, Olafur A
Johannsson, Oskar T
Agnarsson, Bjarni A
Olafsdottir, Gudridur H
Alexiusdottir, Kristin K
Munoz Mitev, Rodrigo
Olafsdottir, Elinborg J
Barkardottir, Rosa B
Eyfjord, Jorunn E
Narod, Steven A
MetadataShow full item record
CitationOestrogen receptor status, treatment and breast cancer prognosis in Icelandic BRCA2 mutation carriers. 2016, 115 (7):776-83 Br. J. Cancer
AbstractThe impact of an inherited BRCA2 mutation on the prognosis of women with breast cancer has not been well documented. We studied the effects of oestrogen receptor (ER) status, other prognostic factors and treatments on survival in a large cohort of BRCA2 mutation carriers.
We identified 285 breast cancer patients with a 999del5 BRCA2 mutation and matched them with 570 non-carrier patients. Clinical information was abstracted from patient charts and pathology records and supplemented by evaluation of tumour grade and ER status using archived tissue specimens. Univariate and multivariate hazard ratios (HR) were estimated for breast cancer-specific survival using Cox regression. The effects of various therapies were studied in patients treated from 1980 to 2012.
Among mutation carriers, positive ER status was associated with higher risk of death than negative ER status (HR=1.94; 95% CI=1.22-3.07, P=0.005). The reverse association was seen for non-carriers (HR=0.71; 95% CI: 0.51-0.97; P=0.03).
Among BRCA2 carriers, ER-positive status is an adverse prognostic factor. BRCA2 carrier status should be known at the time when treatment decisions are made.
DescriptionTo access publisher's full text version of this article click on the hyperlink at the bottom of the page
- Oestrogen receptor status and survival in women with BRCA2-associated breast cancer.
- Authors: Metcalfe K, Lynch HT, Foulkes WD, Tung N, Olopade OI, Eisen A, Lerner-Ellis J, Snyder C, Kim SJ, Sun P, Narod SA
- Issue date: 2019 Feb
- The combined endocrine receptor in breast cancer, a novel approach to traditional hormone receptor interpretation and a better discriminator of outcome than ER and PR alone.
- Authors: Campbell EJ, Tesson M, Doogan F, Mohammed ZMA, Mallon E, Edwards J
- Issue date: 2016 Oct 11
- Tumour diploidy and survival in breast cancer patients with BRCA2 mutations.
- Authors: Tryggvadottir L, Olafsdottir EJ, Olafsdottir GH, Sigurdsson H, Johannsson OT, Bjorgvinsson E, Alexiusdottir K, Stefansson OA, Agnarsson BA, Narod SA, Eyfjord JE, Jonasson JG
- Issue date: 2013 Jul
- Prostate cancer progression and survival in BRCA2 mutation carriers.
- Authors: Tryggvadóttir L, Vidarsdóttir L, Thorgeirsson T, Jonasson JG, Olafsdóttir EJ, Olafsdóttir GH, Rafnar T, Thorlacius S, Jonsson E, Eyfjord JE, Tulinius H
- Issue date: 2007 Jun 20
- The BARD1 Cys557Ser variant and breast cancer risk in Iceland.
- Authors: Stacey SN, Sulem P, Johannsson OT, Helgason A, Gudmundsson J, Kostic JP, Kristjansson K, Jonsdottir T, Sigurdsson H, Hrafnkelsson J, Johannsson J, Sveinsson T, Myrdal G, Grimsson HN, Bergthorsson JT, Amundadottir LT, Gulcher JR, Thorsteinsdottir U, Kong A, Stefansson K
- Issue date: 2006 Jul